The estimated Net Worth of Dennis Langer is at least $4.23 Milión dollars as of 3 August 2021. Dennis Langer owns over 30,000 units of Myriad Genetics stock worth over $3,141,170 and over the last 21 years he sold MYGN stock worth over $697,112. In addition, he makes $392,488 as Independent Director at Myriad Genetics.
Sign up
Dennis Langer MYGN stock SEC Form 4 insiders trading
Dennis has made over 14 trades of the Myriad Genetics stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 30,000 units of MYGN stock worth $761,700 on 3 August 2021.
The largest trade he's ever made was exercising 70,000 units of Myriad Genetics stock on 29 November 2012 worth over $1,249,500. On average, Dennis trades about 7,692 units every 102 days since 2004. As of 3 August 2021 he still owns at least 119,527 units of Myriad Genetics stock.
You can see the complete history of Dennis Langer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dennis Langer biography
Dr. Dennis H. Langer J.D. M.D. serves as an Independent Director of Myriad Genetics, Inc. From January 2013 to July 2014 he served as Chairman and Chief Executive Officer of AdvanDx, Inc. From August 2005 to May 2010, Dr. Langer served as Managing Partner of Phoenix IP Ventures, LLC. From January 2004 to July 2005, he was President, North America for Dr. Reddy’s Laboratories, Inc. From September 1994 until January 2004, Dr. Langer held several high-level positions at GlaxoSmithKline, and its predecessor, SmithKline Beecham, including most recently as a Senior Vice President of Research and Development. He has a broad base of experience in innovative R&D companies such as Eli Lilly, Abbott and Searle. He is also a clinical professor at the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer received a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University. He currently serves on the Board of Directors of Dicerna Pharmaceuticals, Inc. and Pernix Therapeutics Holdings, Inc. During the past five years, Dr. Langer served on the Board of Delcath Systems, Inc.
What is the salary of Dennis Langer?
As the Independent Director of Myriad Genetics, the total compensation of Dennis Langer at Myriad Genetics is $392,488. There are 11 executives at Myriad Genetics getting paid more, with R. Bryan Riggsbee having the highest compensation of $3,138,980.
How old is Dennis Langer?
Dennis Langer is 67, he's been the Independent Director of Myriad Genetics since 2004. There are 3 older and 23 younger executives at Myriad Genetics. The oldest executive at Myriad Genetics, Inc. is Walter Gilbert, 87, who is the Independent Vice Chairman of the Board.
What's Dennis Langer's mailing address?
Dennis's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Insiders trading at Myriad Genetics
Over the last 22 years, insiders at Myriad Genetics have traded over $51,783,466 worth of Myriad Genetics stock and bought 61,160 units worth $1,252,955 . The most active insiders traders include Jerry S Lanchbury, Peter D Meldrum a Arthur H Jr Hayes. On average, Myriad Genetics executives and independent directors trade stock every 18 days with the average trade being worth of $563,312. The most recent stock trade was executed by Heinrich Dreismann on 9 September 2024, trading 10,000 units of MYGN stock currently worth $270,500.
What does Myriad Genetics do?
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
What does Myriad Genetics's logo look like?
Complete history of Dennis Langer stock trades at Dicerna Pharmaceuticals Inc a Myriad Genetics
Myriad Genetics executives and stock owners
Myriad Genetics executives and other stock owners filed with the SEC include:
-
R. Bryan Riggsbee,
Chief Financial Officer, Executive Vice President, Treasurer -
Bernard Tobin,
President - Myriad Autoimmune -
Jerry Lanchbury,
Chief Scientific Officer -
Paul J. Diaz,
CEO, Pres & Director -
R. Bryan Riggsbee,
Exec. VP, CFO & Treasurer -
Dr. Jerry S. Lanchbury Ph.D.,
Chief Scientific Officer -
Dr. Jerry S. Lanchbury,
Chief Scientific Officer -
Mark S. Verratti,
Pres of Myriad Neuroscience & Autoimmune -
Nicole Lambert,
Chief Operating Officer -
John Henderson,
Independent Director -
S. Louise Phanstiel,
Independent Chairman of the Board -
Dennis Langer,
Independent Director -
Heiner Dreismann,
Independent Director -
Lawrence Best,
Independent Director -
Walter Gilbert,
Independent Vice Chairman of the Board -
Daniel Spiegelman,
Independent Director -
Daniel Skovronsky,
Independent Director -
Colleen Reitan,
Independent Director -
Lee Newcomer,
Independent Director -
Rashmi Kumar,
Independent Director -
Mark Pollack,
Chief Medical Officer -
Gary King,
Executive Vice President - International Operations -
Benjamin Jackson,
Executive Vice President, General Counsel, Secretary -
Mark Verratti,
President - Myriad Neuroscience -
Ralph McDade,
President - Myriad RBM -
Nicole Lambert,
President - Myriad Oncology -
Paul Diaz,
President, Chief Executive Officer, Director -
Pamela Wong,
Chief Legal Officer -
Nathan Smith,
Sr. VP of Investor Relations & Treasury -
Dr. Kevin Richard Haas,
Chief Technology Officer -
Paul Chip Parkinson,
Exec. VP of Reimbursement Strategy -
Jayne Baird Hart,
Exec. VP of HR -
Dr. Clivetty Martinez,
Chief Compliance Officer -
Benjamin Jackson,
Exec. VP, Gen. Counsel & Sec. -
Scott Gleason,
Sr. VP of Investor Relations -
Kevin Richard Haas,
Chief Technology Officer -
Alexander Ford,
Chief Operating Officer -
Kevin Richard Haas,
Chief Technology Officer -
Heinrich Dreismann,
Director -
Richard Wenstrup,
Chief Medical Officer -
Virginia Drosos,
President Assurex Health -
Richard M Marsh,
V.P., General Counsel -
Mark Christopher Capone,
President & C.E.O. -
Samraat S. Raha,
Chief Operating Officer -
Pamela Wong,
Chief Legal Officer -
Walter Lloyd Sanders,
President Myriad Oncology -
Linda S Wilson,
Director -
Mark H Skolnick,
Chief Scientific Officer -
Gerald P. Belle,
Director -
Adrian N Hobden,
President -
W Wayne Laslie,
Chief Operating Officer, MPI -
Robert S Attiyeh,
Director -
Dale A Stringfellow,
Director -
Arthur Hull Jr Hayes,
Director -
Arthur H Jr Hayes,
Director -
William A Iii Hockett,
Vice President -
Gregory C Critchfield,
President -
Jay M Moyes,
Chief Financial Officer -
S George Simon,
Vice President -
Robert Gardner Harrison,
Chief Information Officer -
Ronald S. Rogers,
Exec VP Corp Communications -
James S Evans,
V.P. Finance -
T Craig Benson,
President, Myriad RBM -
Paul Bisaro,
Director -
Eric Santa,
Former Chief Growth Officer -
Paul Parkinson,
Fmr EVP Strategy & Innovation -
Margaret Ancona,
SVP, Chief of Staff -
Dale Muzzey,
Chief Scientific Officer -
Natalie Munk,
Chief Accounting Officer -
Heinrich Dreismann,
Director -
Jayne B. Hart,
See Remarks -
Shereen Solaiman,
Chief People Officer -
Scott J. Leffler,
Chief Financial Officer -
Jennifer Lynne Fox,
Chief Legal Officer